Trial · NCT01997333
Results by group25
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 25
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) | Capecitabine | 2.8 | 95% Confidence Interval 1.6 to 3.2 | months | |
| Progression Free Survival (PFS) | CDX-011 | 2.9 | 95% Confidence Interval 2.8 to 3.5 | months | |
| Objective Response Rate (ORR) | Capecitabine | 21 | 95% Confidence Interval 14 to 30 | percentage of participants | |
| Objective Response Rate (ORR) | CDX-011 | 26 | 95% Confidence Interval 20 to 33 | percentage of participants | |
| Duration of Response | Capecitabine | 4.2 | 95% Confidence Interval 2.7 to 5.6 | months | |
| Duration of Response | CDX-011 | 2.8 | 95% Confidence Interval 2.3 to 5.5 | months | |
| Overall Survival | Capecitabine | 8.7 | 95% Confidence Interval 6.9 to 10.8 | months | |
| Overall Survival | CDX-011 | 8.9 | 95% Confidence Interval 7.9 to 10.5 | months | |
| Adverse Events (AE) | Capecitabine | Patients with at least 1 AE | 92 | Participants | |
| Adverse Events (AE) | CDX-011 | Patients with at least 1 AE | 211 | Participants | |
| Adverse Events (AE) | Capecitabine | Patients with at least 1 treatment related AE | 84 | Participants | |
| Adverse Events (AE) | CDX-011 | Patients with at least 1 treatment related AE | 204 | Participants | |
| Adverse Events (AE) | Capecitabine | Patients with Grade 1 treatment related AE | 7 | Participants | |
| Adverse Events (AE) | CDX-011 | Patients with Grade 1 treatment related AE | 7 | Participants | |
| Adverse Events (AE) | Capecitabine | Patients with Grade 2 treatment related AE | 33 | Participants | |
| Adverse Events (AE) | CDX-011 | Patients with Grade 2 treatment related AE | 54 | Participants | |
| Adverse Events (AE) | Capecitabine | Patients with Grade 3 treatment related AE | 44 | Participants | |
| Adverse Events (AE) | CDX-011 | Patients with Grade 3 treatment related AE | 114 | Participants | |
| Adverse Events (AE) | Capecitabine | Patients with Grade 4 treatment related AE | 8 | Participants | |
| Adverse Events (AE) | CDX-011 | Patients with Grade 4 treatment related AE | 32 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01997333/results